Skip to main
ACLX

Arcellx (ACLX) Stock Forecast & Price Target

Arcellx (ACLX) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Arcellx Inc. has demonstrated robust sales growth in its CAR T therapy, with Carvykti experiencing an average quarterly growth of 32% over the last 12 quarters and achieving a remarkable year-over-year revenue increase of 214%. The expanding adoption of CAR T therapy among community physicians, rising from 29% to 47%, indicates a growing acceptance and market penetration, further solidifying the company's position in the sector. Additionally, Arcellx's anito-cel product shows promise for capturing a significant share of the market, with projected sales of $4.7 billion by 2035, supported by its improved profile compared to existing options.

Bears say

The financial outlook for Arcellx, Inc. appears negative due to concerning clinical trial results, particularly the high rate of Grade 3-4 infections observed in its MajesTEC-1 study, which raises doubts about the safety and tolerability of its therapies. Additionally, the company's market share estimates for its anito-cel treatment align closely with consensus, yet its overall sales projections for the CAR T market in myeloma fall significantly below industry expectations, indicating potential revenue challenges. Furthermore, barriers to CAR T therapy adoption in community settings suggest that even with a promising portfolio, translating clinical success into widespread use and market penetration may remain problematic.

Arcellx (ACLX) has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arcellx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arcellx (ACLX) Forecast

Analysts have given Arcellx (ACLX) a Buy based on their latest research and market trends.

According to 8 analysts, Arcellx (ACLX) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $113.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $113.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arcellx (ACLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.